Trial · NCT07891988
Preventing Kidney Injury Using Carbon Dioxide as Contrast Medium in Patients With Peripheral Arterial Disease (PAD) and Chronic Kidney Disease (CKD) Having Arterial Intervention
NCT07891988, Not applicable, Active not recruiting, University of Leicester
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Preventing Kidney Injury Using Carbon Dioxide as Contrast Medium in Patients With Peripheral Arterial Disease (PAD) and Chronic Kidney Disease (CKD) Having Arterial Intervention. Trials, record NCT07891988. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891988
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Preventing Kidney Injury Using Carbon Dioxide as Contrast Medium in Patients With Peripheral Arterial Disease (PAD) and Chronic Kidney Disease (CKD) Having Arterial Intervention
- NCT number
- NCT07891988
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 184 participants, actual
- Lead sponsor
- University of Leicester
- Conditions
- Peripheral Arterial Disease, Chronic Kidney Diseases, Acute Kidney Injury
- Interventions
- Iodinated contrast medium, CO2 automated injector contrast medium
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Renal Function: Log Serum Creatinine | 2, 30, and 90 days after endovascular revascularisation | Assessment of short and medium-term renal decline by measuring serum creatinine from blood samples processed at local pathology laboratories. Unit of Measure: log(µmol/L). Renal decline or "worsening of kidney function" is defined as a \>25% decline in the estimated Glomerular Filtration Rate (eGFR) from the baseline assessment. The baseline eGFR is defined as the most recent value recorded prior to the procedure. Additionally, the trial measures short and medium-term renal decline by tracking changes in Log serum creatinine at 2, 30, and 90 days post-procedure, and evaluates the onset of Acute Kidney Injury (AKI) based on the KDIGO criteria. |
| Secondary | Volume of iodinated contrast medium used | Intraoperative (during the index procedure) | Measurement of the overall volume of iodinated contrast medium required to complete the endovascular revascularisation procedure. Unit of Measure: Milliliters (ml) |
| Secondary | Incidence of Acute Kidney Injury (AKI) | Within 2 days (48 hours) of the procedure | Assessment of the development of acute kidney injury evaluated using the Kidney Disease Improving Global Outcomes (KDIGO) criteria. Unit of Measure: Percentage (%) of participants |
| Secondary | Proportion of participants developing Major Adverse Kidney Events (MAKE) | By 90 day post index procedure follow-up | The development of a major adverse kidney event, defined as either death, new requirement for dialysis, or worsening kidney function indicated by a \>25% decline in estimated Glomerular Filtration Rate (eGFR) from baseline. Unit of Measure: Percentage (%) of participants |
| Secondary | Inpatient stay duration | By 90 day post index procedure follow-up | The length of time the participant spent as an inpatient since randomisation. Unit of Measure: Days |
| Secondary | Pain experienced during the procedure | During the index procedure (measured at the first and final angiogram) | Assessment of the pain experienced by the participant during the injection of the contrast medium, measured using a Visual Analogue Scale (VAS). The scale ranges from 0 to 10, where 0 indicates no pain and 10 indicates the worst possible pain. Unit of Measure: Score on a scale from 0 to 10 |
| Secondary | Quality of Life: EQ-5D-5L | Baseline and 90 days post-procedure | Assessment of health-related quality of life measured using the EuroQOL 5D 5L (EQ-5D-5L) Questionnaire. It assesses 5 dimensions on a 1-5 scale and includes a visual analogue scale rating current health from 0 (worst) to 100 (best). Unit of Measure: Score on a scale from 0 to 100 |
| Secondary | Quality of Life: SF-36 | Time Frame: Baseline and 90 days post-procedure | Assessment of health-related quality of life measured using the 36-Item Short Form Health Survey (SF-36) Questionnaire, which covers eight domains of health converted into a total score indicating low to high quality of life. Unit of Measure: Total score |
| Secondary | Planned Revascularisation Completion Rate | Intraoperative (during the index procedure) | Evaluation of the technical success of the intervention by calculating the proportion of endovascular revascularisation procedures that were completed as originally planned. Unit of Measure: Percentage (%) of participants |
| Secondary | Number of Re-interventions | By 90 day post index procedure follow-up | Tracking the total number of subsequent surgical or endovascular re-interventions required. Unit of Measure: Number of interventions |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891988
GET https://conductscience.org/api/trials/v1/NCT07891988/registered